<DOC>
	<DOCNO>NCT00536991</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose calcitriol give combination ketoconazole therapeutic hydrocortisone see well work treat patient prostate cancer . Calcitriol may help prostate cancer cell become like normal cell grow spread slowly . Ketoconazole therapeutic hydrocortisone may help calcitriol work well make tumor cell sensitive drug . Giving calcitriol together ketoconazole therapeutic hydrocortisone may better treatment prostate cancer .</brief_summary>
	<brief_title>Calcitriol Combination With Ketoconazole Therapeutic Hydrocortisone Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) oral calcitriol daily x 3 consecutive day week combination oral ketoconazole ( 400 mg thrice daily [ TID ] ) + oral hydrocortisone ( 20 mg AM , 10 mg PM ) men androgen independent prostate cancer ( AIPC ) . ( Phase I ) II . To estimate prostate-specific antigen ( PSA ) response rate . ( Phase II ) SECONDARY OBJECTIVES : I . To evaluate pharmacokinetics phase II dose oral calcitriol without ketoconazole ( 400 mg TID ) . II . Describe objective tumor response combination oral calcitriol ketoconazole hydrocortisone among patient measurable disease use Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . III . Determine toxicities tolerability oral calcitriol combination daily oral ketoconazole hydrocortisone . OUTLINE : This phase I , dose-escalation study calcitriol follow phase II study . PHASE I : Patients receive calcitriol orally ( PO ) daily ( QD ) day 1-3 , 8-10 , 15-17 , 22-24 . Patients also receive ketoconazole PO TID day 1-24 therapeutic hydrocortisone PO twice daily ( BID ) day -1 24 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PHASE II : Patients receive calcitriol therapeutic hydrocortisone phase I . Patients also receive ketoconazole PO TID day 4-24 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma consistent clinically androgen independent prostate cancer Measurable disease elevate PSA evaluable disease ( PSA elevation constitute evaluable disease ) = &lt; 2 regimen cytotoxic chemotherapy prior study entry ; retinoids , vitamin D analogue , peroxisome proliferatoractivated receptor ( PPAR ) gamma agonist antagonist , antiandrogens , progestational agent , estrogen , prostate cancer ( PC ) SPES , luteinizing hormonereleasing hormone ( LHRH ) analogue , vaccine , cytokine consider `` cytotoxics '' ; patient previously receive ketoconazole + glucocorticoid eligible trial Patients receive antiandrogens progestational agent therapy prostate cancer must discontinue therapy demonstrate rise PSA &gt; = 28 day follow discontinuation ( antiandrogen withdrawal AAW ) ( &gt; = 42 day bicalutamide nilutamide ) ; patient receive megestrol acetate therapy `` hot flash '' dose = &lt; 40 mg per day may continue therapy trial ; dose megestrol acetate change protocol treatment ; patient undergo androgen deprivation use LHRH analogue must continue agent undergo orchiectomy maintain castrate level testosterone Patients must prostate cancer advanced recurrent standard curative reliable palliative therapy exist longer effective Patients receive chemotherapy investigational agent least 4 week enter study ( 6 week nitrosoureas mitomycin C ) Eastern Clinical Oncology Group performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy &gt; 3 month Leukocytes : &gt; = 3,000/ul Hemoglobin : &gt; = 8 g/dl Absolute neutrophil count ( ANC ) : &gt; = 1,500/ul Platelets : &gt; = 75,000/ul Total bilirubin : within normal institutional limit Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) : = &lt; 2.5 x institutional upper limit normal Creatine : = &lt; 2 mg/dL Calcium : normal institutional limit Patients able receive oral medication Patients brain metastasis stable treated surgery irradiation eligible trial Men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately Ability understand willingness sign write informed consent document PHASE II GROUP B : Progressive disease must occur abiraterone within prior 12 month patient receive treatment enzalutamide Men ethnic group eligible trial ; effort make include minority group representative ethnicity race community service Roswell Park Cancer Institute ( RPCI ) Known severe hypersensitivity ketoconazole , calcitriol excipients product History allergic reaction attribute compound similar chemical biologic composition calcitriol , ketoconazole , agent use study Evidence significant clinical disorder laboratory find make undesirable patient participate trial History kidney , ureteral , bladder stone within last 5 year Heart failure significant heart disease include significant arrhythmia , myocardial infarction within last 3 month , unstable angina , document ejection fraction &lt; 30 % , current digoxin therapy Thiazide therapy within 7 day enter study Requirement concurrent systemic glucocorticoid therapy great physiologic replacement dose Unwillingness stop calcium supplementation As judged investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would light compliance study requirement Human immunodeficiency viruspositive patient receive combination antiretroviral therapy exclude study Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , phenobarbital , St John 's wort , alfentanil , alfuzosin , almotriptan , alprazolam , amiodarone , amitriptyline , amprenavir , aprepitant , aripiprazole , bepridil , bortezomib , bosentan , budesonide , buprenorphine , buspirone , carbamazepine , cilostazol , cisapride , cyclosporine , delavirdine , didanosine , digoxin , disopyramide dofetilide , donepezil , eletriptan , eplerenone , fluticasone , fosamprenavir , galantamine , systemic griseofulvin , indinavir , levobupivacaine , lopinavir , midazolam , mifepristone , modafinil , nateglinide , nefazodone , nelfinavir , oxcarbazepine , pimozide , quetiapine , quinidine , repaglinide , rifabutin , rifampin , rifapentine , ritonavir , saquinavir , sildenafil , sirolimus , tacrolimus , tadalafil , tolterodine , theophylline , tolterodine , triazolam , valdecoxib , vardenafil , ziprasidone , zonisamide , statin , exception pravastatin ( Pravachol ) `` statin '' metabolize induce cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) , calcium channel blocker , Coumadin macrolides agent significantly perturb clinically important way P450 inhibitory property ketoconazole Concomitant use proton pump inhibitor histamine ( H ) 2 blocker Treatment nonapproved investigational drug agent within 30 day day 1 trial treatment Any unresolved chronic toxicity great Common Terminology Criteria ( CTC ) grade 2 previous anticancer therapy Incomplete heal previous oncologic treatment major surgery Inability swallow oral capsule Patients digoxin exclude study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>